The Conversation (0)
DiaMedica Therapeutics received a patent for DM199 from the US Patent and Trademark Office.
DiaMedica Therapeutics (TSXV:DMA, OTCQB:DMCAF) received a patent for DM199 from the US Patent and Trademark Office.
As quoted in the press release:
The patent protects the methods of parenterally administrating DM199 to patients in need where absorption into the circulation via methods such as intravenous (“IV”) or subcutaneous administration improves systemic pharmacokinetics (“PK”), bioavailability, safety, and/or convenience related to IV or other forms of administration. The patent has an expiration date of 2035, which does not include any potential patent term extension.
“We are very excited to have received additional patent protection covering parenteral delivery, including subcutaneous and IV administration and related methods,” said Rick Pauls, President & CEO of DiaMedica Therapeutics. “We believe these methods of delivery could more completely address the needs of patients by offering better options for acute and chronic therapy.”
Click here to read the full press release.
Source: www.marketwired.com
